Revance Therapeutics reported $120.16M in Equity Capital and Reserves for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Equity Capital And Reserves Change
Adamas Pharmaceuticals ADMS:US -21606000 17.57M
Aerie Pharmaceuticals AERI:US $ -72.88M 33.26M
ALKERMES ALKS:US $ 1096.17M 1.73M
Biodelivery Sciences International BDSI:US $ 122.78M 8.86M
Bristol Myers Squibb BMY:US $ 37213M 405M
Cara Therapeutics CARA:US $ 207.19M 3.72M
Coherus Biosciences CHRS:US $ 130.76M 25.46M
Eli Lilly And LLY:US $ 7757M 1312.6M
Endo International Ordinary Shares ENDP:US $ -690.32M 73.28M
Flexion Therapeutics FLXN:US $ -82377000 26.21M
Gw Pharmaceuticals GWPH:US $ 736.37M 4.72M
Horizon Pharma HZNP:US $ 4450.21M 376.58M
JAZZ PHA JAZZ:US $ 3938.48M 193.01M
Neurocrine Biosciences NBIX:US $ 1346M 66.8M
Pacira Pharmaceuticals PCRX:US $ 718.6M 31.43M
Procter & Gamble PG:US $ 46111M 267M
Revance Therapeutics RVNC:US $ 120.16M 66.07M
Supernus Pharmaceuticals SUPN:US $ 810.47M 24.89M
Teva Pharmaceutical Industries TEVA:US $ 10467M 143M
Zogenix ZGNX:US $ 224.3M 48.56M